News
RARE
46.82
+2.99%
1.36
Weekly Report: what happened at RARE last week (0318-0322)?
Weekly Report · 2d ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. Granted 13,020 restricted stock units to eight newly hired non-executive officers of the company. The company is a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases.
Barchart · 5d ago
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)
TipRanks · 03/19 11:10
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical (NASDAQ:RARE) underwent analysis by 8 analysts in the last quarter. The company has an average 12-month price target of $92.75. Ultragenyx pharmaceutical is a biopharmaceutical company developing drugs for the treatment of rare diseases.
Benzinga · 03/18 13:00
Ultragenyx Pharma Is Maintained at Overweight by JP Morgan
Dow Jones · 03/18 12:08
Ultragenyx Pharma Price Target Raised to $92.00/Share From $88.00 by JP Morgan
Dow Jones · 03/18 12:08
JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $92
Benzinga · 03/18 11:57
Weekly Report: what happened at RARE last week (0311-0315)?
Weekly Report · 03/18 09:27
3 Best Stocks to Buy Now, 3/15/2024, According to Top Analysts 
TipRanks · 03/15 06:00
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Cannabist Company Holdings (OtherCBSTF)
TipRanks · 03/14 10:50
Ultragenyx Pharmaceutical (NASDAQ:RARE shareholders incur further losses as stock declines 7.4% this week, taking three-year losses to 63%
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has lost 63% in the last three years. The share price of the company is down 7.4% over the last week. In the past three years, the company's revenue has grown by 10% per year. The company made a loss in the past 12 months. It's worth taking a look at business performance to see if there are any red flags.
Simply Wall St · 03/13 13:13
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
RegenXBIO Inc. (NASDAQ:RGNX) has made remarkable progress in advancing its pipeline of gene therapies. The company has reported positive interim results from a study using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. It is also on track to file a BLA for its MPS II program in 2024. The odds of the company reaching the finish line have been upgraded from buy to strong buy. Its NAV Technology Platform is building upon next-generation AAV vectors to enhance efficacy.
Seeking Alpha · 03/11 15:53
Weekly Report: what happened at RARE last week (0304-0308)?
Weekly Report · 03/11 09:26
Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Ultragenyx Pharmaceutical's stock has increased by approximately 9% but lags behind the S&P's return of 28%. The article assesses Ultragenyx's current merits per its recently reported Q4, 2023 earnings as we progress into 2024. The company has a diverse growing revenue stream in 2023.
Seeking Alpha · 03/09 14:55
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
Weekly Report: what happened at RARE last week (0226-0301)?
Weekly Report · 03/04 09:27
Ultragenyx Pharma Is Maintained at Overweight by JP Morgan
Dow Jones · 02/27 18:26
Ultragenyx Pharma Price Target Raised to $88.00/Share From $84.00 by JP Morgan
Dow Jones · 02/27 18:26
Ultragenyx Pharma Price Target Announced at $107.00/Share by Cantor Fitzgerald
Dow Jones · 02/27 14:37
Ultragenyx Pharma Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 02/27 14:37
More
Webull provides a variety of real-time RARE stock news. You can receive the latest news about Ultragenyx Pharm through multiple platforms. This information may help you make smarter investment decisions.
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.